HepaRegeniX Raises €15M For HRX-215 Liver Regeneration Development
10 Jul 2024 //
GLOBENEWSWIRE
HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215
14 Mar 2024 //
GLOBENEWSWIRE
HepaRegeniX Appoints Elias Papatheodorou as New Chairman of Board of Directors
30 Mar 2022 //
ACCESSWIRE
HepaRegeniX initiates first-in-man Ph1 trial for lead MKK4 inhibitor HRX 0215
10 Aug 2021 //
PIPELINEREVIEW
HepaRegeniX initiates first-in-man Ph1 trial for lead MKK4 inhibitor HRX 0215
10 Aug 2021 //
PIPELINEREVIEW